Albert Akhobekov
Research Subjects
Albert Akhobekov has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Pervin A. Zeynalova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Clinical Hospital "Lapino" of the "Mother and Child" Group of Companies
10 shared publications - Yulia E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
7 shared publications Ю. Е. Рябухина
Клинический госпиталь «Лапино» группы компаний «Мать и дитя
6 shared publications- Firuza М. Abbasbeyli
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
4 shared publications - T. I. Kopaliani
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
4 shared publications - O. L. Timofeeva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
3 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 80-91
Diagnostic features and treatment approaches for AL amyloidosis: a literature review and clinical case report
AL amyloidosis (ALA) is a disease characterized by the deposition of immunoglobulins monoclonal free light chains fragments with impaired organ function. Despite advances in the treatment of plasma cell dyscrasias, determining optimal approaches to treating ALA patients remains a challenging task. Research results and real-world clinical practice data indicate the advantage of using a combination of daratumumab with a bortezomib-containing regimen over other programs in achieving an antitumor response, increasing progression-free survival, while remaining a highly effective treatment option with a favorable safety profile in most patients. It is advisable to study the prognostic role of minimal residual disease in ALA patients and its correlation with the achieved hematological and organ responses at different treatment stages, as well as to search for new biological markers for patients’ risk stratification and optimization of antitumor therapy. Clinical case of a patient with stage II ALA are presented. After six cycles of Dara-VCD (daratumumab, bortezomib, cyclophosphamide, and dexamethasone), a very good partial hematologic response was recorded. Despite the fact that the patient had previously received VCD (bortezomib, cyclophosphamide, and dexamethasone) and daratumumab alone in the second line, significant treatment efficacy, along with a significant improvement in overall condition and quality of life, was achieved only with the use of bortezomib-containing therapy in combination with an anti-CD38 antibody.
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 80-91
Open AccessDiagnostic features and treatment approaches for AL amyloidosis: a literature review and clinical case report
AL amyloidosis (ALA) is a disease characterized by the deposition of immunoglobulins monoclonal free light chains fragments with impaired organ function. Despite advances in the treatment of plasma cell dyscrasias, determining optimal approaches to treating ALA patients remains a challenging task. Research results and real-world clinical practice data indicate the advantage of using a combination of daratumumab with a bortezomib-containing regimen over other programs in achieving an antitumor response, increasing progression-free survival, while remaining a highly effective treatment option with a favorable safety profile in most patients. It is advisable to study the prognostic role of minimal residual disease in ALA patients and its correlation with the achieved hematological and organ responses at different treatment stages, as well as to search for new biological markers for patients’ risk stratification and optimization of antitumor therapy. Clinical case of a patient with stage II ALA are presented. After six cycles of Dara-VCD (daratumumab, bortezomib, cyclophosphamide, and dexamethasone), a very good partial hematologic response was recorded. Despite the fact that the patient had previously received VCD (bortezomib, cyclophosphamide, and dexamethasone) and daratumumab alone in the second line, significant treatment efficacy, along with a significant improvement in overall condition and quality of life, was achieved only with the use of bortezomib-containing therapy in combination with an anti-CD38 antibody.
- 1 January 2026
- Published by Federal Research Institute for Health Organization and Informatics in Social Aspects of Population Health
- Vol. 72 (3) , 4
ASSESSMENT OF ONCOLOGISTS’ AND CARDIOLOGISTS’ AWARENESS OF COMPLICATIONS ASSOCIATED WITH ANTITUMOR THERAPY AND HOW MEDICAL CARE IS ORGANIZED FOR PATIENTS UNDERGOING SUCH TREATMENT
Significance. Despite advances in diagnosis and treatment, malignant neoplasms, along with cardiovascular diseases, remain the leading causes of death. Cardio-oncology is an emerging interdisciplinary field focused on prevention, diagnosis, and treatment of cardiovascular diseases in patients with cancer. In Russia, cardio-oncology programs are still implemented on a limited scale. Purpose. To study the opinions of cardiologists and oncologists about cardio-oncology to assess their awareness of preventive measures for cardiovascular complications in cancer patients and specifics of organizing care delivery to such patients. Material and methods. A sociological survey was conducted from April 30, 2025, to July 31, 2025. The survey’s structured questionnaire included 26 questions regarding medical specialists’ awareness of cardio-oncology, attitudes towards the development of cardio-oncology departments, barriers to their development, and assessment of their knowledge in the field of cardio-oncology. Data processing was performed using Statistica 14 software package. Sociological, analytical, and statistical research methods were used. Results. 113 physicians participated in the survey, including 67 oncologists (59.3%) and 46 cardiologists (40.7%). Of the 113 respondents, 44 (38.9%) were unaware of this specialty, while 69 (61.1%) were aware of it. The overwhelming majority of the surveyed physicians (105 (92.9%)) reported encountering cardiovascular complications in patients receiving antitumor therapy. Discussion. The results of the sociological study indicate a significant clinical need for cardio-oncology care, while also demonstrating a systemic knowledge gap in the organization of medical care delivery to cancer patients and insufficient awareness among specialists regarding the risks of cardiovascular complications in cancer patients receiving antitumor therapy. Conclusion. In Russia, there is an objective need to introduce cardio-oncology as a new specialized area of care organization for patients with malignant neoplasms. However, its implementation is hampered by a lack of structured knowledge, standardized protocols, and problems with coordination between medical specialists. Keywords: malignant neoplasms of lymphoid and hematopoietic tissues; cardio-oncology; antitumor therapy; cardiovascular toxicity.
- 1 January 2026
- Published by Federal Research Institute for Health Organization and Informatics in Social Aspects of Population Health
- Vol. 72 (3) , 4
ASSESSMENT OF ONCOLOGISTS’ AND CARDIOLOGISTS’ AWARENESS OF COMPLICATIONS ASSOCIATED WITH ANTITUMOR THERAPY AND HOW MEDICAL CARE IS ORGANIZED FOR PATIENTS UNDERGOING SUCH TREATMENT
Significance. Despite advances in diagnosis and treatment, malignant neoplasms, along with cardiovascular diseases, remain the leading causes of death. Cardio-oncology is an emerging interdisciplinary field focused on prevention, diagnosis, and treatment of cardiovascular diseases in patients with cancer. In Russia, cardio-oncology programs are still implemented on a limited scale. Purpose. To study the opinions of cardiologists and oncologists about cardio-oncology to assess their awareness of preventive measures for cardiovascular complications in cancer patients and specifics of organizing care delivery to such patients. Material and methods. A sociological survey was conducted from April 30, 2025, to July 31, 2025. The survey’s structured questionnaire included 26 questions regarding medical specialists’ awareness of cardio-oncology, attitudes towards the development of cardio-oncology departments, barriers to their development, and assessment of their knowledge in the field of cardio-oncology. Data processing was performed using Statistica 14 software package. Sociological, analytical, and statistical research methods were used. Results. 113 physicians participated in the survey, including 67 oncologists (59.3%) and 46 cardiologists (40.7%). Of the 113 respondents, 44 (38.9%) were unaware of this specialty, while 69 (61.1%) were aware of it. The overwhelming majority of the surveyed physicians (105 (92.9%)) reported encountering cardiovascular complications in patients receiving antitumor therapy. Discussion. The results of the sociological study indicate a significant clinical need for cardio-oncology care, while also demonstrating a systemic knowledge gap in the organization of medical care delivery to cancer patients and insufficient awareness among specialists regarding the risks of cardiovascular complications in cancer patients receiving antitumor therapy. Conclusion. In Russia, there is an objective need to introduce cardio-oncology as a new specialized area of care organization for patients with malignant neoplasms. However, its implementation is hampered by a lack of structured knowledge, standardized protocols, and problems with coordination between medical specialists. Keywords: malignant neoplasms of lymphoid and hematopoietic tissues; cardio-oncology; antitumor therapy; cardiovascular toxicity.
- Open Access
- 5 March 2025
- Published by Publishing House ABV Press in MD-Onco
- Vol. 5 (1) , 59-65
Multidisciplinary approach in management of patients with immune thrombocytopenia and ischemic heart disease
Immune thrombocytopenia in patients with concomitant cardiovascular disorders requiring antiplatelet and anticoagulant therapy can increase the risk of hemorrhages and arterial and venous thromboembolic complications. This situation necessitates special patient management. Multidisciplinary approach is important for patients requiring myocardial revascularization due to the necessity of administration of double or triple antiplatelet therapy.The article presents our experience in management of patients with immune thrombocytopenia and high functional class stable angina requiring coronary artery stent.
- 5 March 2025
- Published by Publishing House ABV Press in MD-Onco
- Vol. 5 (1) , 59-65
Open AccessMultidisciplinary approach in management of patients with immune thrombocytopenia and ischemic heart disease
Immune thrombocytopenia in patients with concomitant cardiovascular disorders requiring antiplatelet and anticoagulant therapy can increase the risk of hemorrhages and arterial and venous thromboembolic complications. This situation necessitates special patient management. Multidisciplinary approach is important for patients requiring myocardial revascularization due to the necessity of administration of double or triple antiplatelet therapy.The article presents our experience in management of patients with immune thrombocytopenia and high functional class stable angina requiring coronary artery stent.
- 1 January 2025
- Published by Federal Research Institute for Health Organization and Informatics in Social Aspects of Population Health
- Vol. 71 (5) , 12
THE PLACE OF MALIGNANT NEOPLASMS OF LYMPHOID AND HEMATOPOIETIC TISSUES IN THE STRUCTURE OF CANCER INCIDENCE IN THE RUSSIAN FEDERATION AND THE MOSCOW REGION
Significance. Malignant neoplasms are a global socio-hygienic and economic problem of the 21st century, being one of the main causes of mortality worldwide. In 2022, about 20 million new cases of cancer and 9.7 million deaths from this cause were registered worldwide. Malignant neoplasms of the lymphoid and hematopoietic tissue account for about 5% of all malignant neoplasms in the world. Purpose. To analyze the incidence rates of malignant neoplasms of lymphoid and hematopoietic tissue and determine their place in the prevalence structure of malignant neoplasms in the Moscow region and the Russian Federation. Material and methods. The analysis of morbidity and mortality data for the period from 2013 to 2023 is based on materials from the "Malignant Neoplasms in Russia" collection of the P.A. Herzen Moscow Oncology Research Institute, a branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, data from federal statistical observation forms No. 12 and 35. The study used epidemiological, information-analytical and mathematical-statistical methods. Statistical data processing was carried out using the licensed Microsoft Office Excel 2016 software. Results. The incidence rate of malignant neoplasms in the Moscow region in 2023 was 341 per 100,000 population, which is 34.9% lower than the Russian average (460 per 100,000 population). The incidence rates of malignant neoplasms of lymphoid and hematopoietic tissue in the Moscow region were also lower than the Russian average (15.3 and 20.6 per 100,000 population, respectively). Discussion. In Russia and the Moscow region, there is an increase in the incidence of malignant neoplasms of lymphoid and hematopoietic tissue by 8.7 and 2.6%, respectively. The decrease in the incidence and mortality rate to 20% in the period from 2020 to 2023 is due to the coronavirus pandemic. Conclusion. The dynamics and trends in the incidence of cancer in general and malignant neoplasms of lymphoid and hematopoietic tissue in the Russian Federation and the Moscow Region in 2013-2023 indicate the need to take measures aimed at increasing the coverage and effectiveness of medical examinations, intensifying scientific and educational work among the population. Keywords: malignant neoplasms of lymphoid and hematopoietic tissue; incidence; mortality; incidence dynamics.
- 1 January 2025
- Published by Federal Research Institute for Health Organization and Informatics in Social Aspects of Population Health
- Vol. 71 (5) , 12
THE PLACE OF MALIGNANT NEOPLASMS OF LYMPHOID AND HEMATOPOIETIC TISSUES IN THE STRUCTURE OF CANCER INCIDENCE IN THE RUSSIAN FEDERATION AND THE MOSCOW REGION
Significance. Malignant neoplasms are a global socio-hygienic and economic problem of the 21st century, being one of the main causes of mortality worldwide. In 2022, about 20 million new cases of cancer and 9.7 million deaths from this cause were registered worldwide. Malignant neoplasms of the lymphoid and hematopoietic tissue account for about 5% of all malignant neoplasms in the world. Purpose. To analyze the incidence rates of malignant neoplasms of lymphoid and hematopoietic tissue and determine their place in the prevalence structure of malignant neoplasms in the Moscow region and the Russian Federation. Material and methods. The analysis of morbidity and mortality data for the period from 2013 to 2023 is based on materials from the "Malignant Neoplasms in Russia" collection of the P.A. Herzen Moscow Oncology Research Institute, a branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, data from federal statistical observation forms No. 12 and 35. The study used epidemiological, information-analytical and mathematical-statistical methods. Statistical data processing was carried out using the licensed Microsoft Office Excel 2016 software. Results. The incidence rate of malignant neoplasms in the Moscow region in 2023 was 341 per 100,000 population, which is 34.9% lower than the Russian average (460 per 100,000 population). The incidence rates of malignant neoplasms of lymphoid and hematopoietic tissue in the Moscow region were also lower than the Russian average (15.3 and 20.6 per 100,000 population, respectively). Discussion. In Russia and the Moscow region, there is an increase in the incidence of malignant neoplasms of lymphoid and hematopoietic tissue by 8.7 and 2.6%, respectively. The decrease in the incidence and mortality rate to 20% in the period from 2020 to 2023 is due to the coronavirus pandemic. Conclusion. The dynamics and trends in the incidence of cancer in general and malignant neoplasms of lymphoid and hematopoietic tissue in the Russian Federation and the Moscow Region in 2013-2023 indicate the need to take measures aimed at increasing the coverage and effectiveness of medical examinations, intensifying scientific and educational work among the population. Keywords: malignant neoplasms of lymphoid and hematopoietic tissue; incidence; mortality; incidence dynamics.
- Open Access
- 14 June 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (2) , 71-77
The role of magnetic resonance imaging in cardio-oncology
In recent decades, groundbreaking methods of diagnosis and treatment were developed leading to significantly increased life span of patients with malignant neoplasms. Among patients treated for cancer, cardiovascular diseases are the leading cause of death not associated with cancer. Early identification of cardiotoxicity is very important as it allows to apply early prevention measures and modify antitumor treatment schemes. Prevention and treatment of cardiotoxicity are possible only with a functioning multidisciplinary team including oncologists and cardiologists. Magnetic resonance imaging of the heart plays a significant role in monitoring the condition of cardiovascular system during antitumor treatment. This technique allows to obtain accurate characteristics of the tissues and evaluate myocardial perfusion without radiation exposure.
- 14 June 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (2) , 71-77
Open AccessThe role of magnetic resonance imaging in cardio-oncology
In recent decades, groundbreaking methods of diagnosis and treatment were developed leading to significantly increased life span of patients with malignant neoplasms. Among patients treated for cancer, cardiovascular diseases are the leading cause of death not associated with cancer. Early identification of cardiotoxicity is very important as it allows to apply early prevention measures and modify antitumor treatment schemes. Prevention and treatment of cardiotoxicity are possible only with a functioning multidisciplinary team including oncologists and cardiologists. Magnetic resonance imaging of the heart plays a significant role in monitoring the condition of cardiovascular system during antitumor treatment. This technique allows to obtain accurate characteristics of the tissues and evaluate myocardial perfusion without radiation exposure.
- Open Access
- 7 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 35-40
Transcatheter prosthetics in post-radiation aortic stenosis: a review of literature
Aortic stenosis belongs to the most common acquired cardiac defects in adults, affecting about 2 % of those over 65 years old and 4 % of those over 85 years old. One of the common causes of aortic stenosis is radiation therapy of the mediastinum for malignant neoplasms localised in the thorax. According to the American Society of Clinical Oncology, 10–30 % of patients receiving radiation therapy tend to develop cardiovascular complications, usually after an average follow-up period of 5 to 10 years. About 80 % of cardiovascular complications of radiation therapy are valve diseases, aortic stenosis accounting for a significant part of them. Radiation causes late cicatrisation, fibrous thickening, retraction and calcification of aortic valve cusps, contributing to the restriction of their movement and therefore to the narrowing of the aortic valve orifice. Patients with aortic valve stenosis have an average lifespan of about 3 years after coronary symptoms or syncopal conditions appear, and about 1.5 years after congestive heart failure begins to manifest. Aortic valve prosthetics is the sole effective and radical treatment method for patients with aortic valve stenosis that allows to improve their condition and prolong their life. Transcatheter aortic valve prosthetics are the treatment of choice in this category of patients.
- 7 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 35-40
Open AccessTranscatheter prosthetics in post-radiation aortic stenosis: a review of literature
Aortic stenosis belongs to the most common acquired cardiac defects in adults, affecting about 2 % of those over 65 years old and 4 % of those over 85 years old. One of the common causes of aortic stenosis is radiation therapy of the mediastinum for malignant neoplasms localised in the thorax. According to the American Society of Clinical Oncology, 10–30 % of patients receiving radiation therapy tend to develop cardiovascular complications, usually after an average follow-up period of 5 to 10 years. About 80 % of cardiovascular complications of radiation therapy are valve diseases, aortic stenosis accounting for a significant part of them. Radiation causes late cicatrisation, fibrous thickening, retraction and calcification of aortic valve cusps, contributing to the restriction of their movement and therefore to the narrowing of the aortic valve orifice. Patients with aortic valve stenosis have an average lifespan of about 3 years after coronary symptoms or syncopal conditions appear, and about 1.5 years after congestive heart failure begins to manifest. Aortic valve prosthetics is the sole effective and radical treatment method for patients with aortic valve stenosis that allows to improve their condition and prolong their life. Transcatheter aortic valve prosthetics are the treatment of choice in this category of patients.
- Open Access
- 7 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 48-51
A clinical case of cardiotoxicity caused by antitumor therapy with osimertinib and bevacizumab
Oncological and cardiovascular diseases are the main causes of mortality worldwide. The rate of these pathologies tends to increase as the population ages. The implementation of highly effective therapeutic schemes has led to a significant increase in the survival rate of oncology patients over the last decades. In many cases, the mortality rate in oncology patients who underwent effective treatment is caused by cardiovascular events arising as a consequence of aggressive antitumor treatment or pre-existing chronic cardiovascular diseases. Among cardiovascular complications that developed both during active treatment of the malignant neoplasm and in the longer term, literature most often mentions cardiac insufficiency. We present a clinical case of successful diagnosis and treatment of severe heart insufficiency caused by antitumor therapy with bevacizumab and osimertinib in a patient with cancer of the upper lobe of the right lung and metastases into the brain.
- 7 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 48-51
Open AccessA clinical case of cardiotoxicity caused by antitumor therapy with osimertinib and bevacizumab
Oncological and cardiovascular diseases are the main causes of mortality worldwide. The rate of these pathologies tends to increase as the population ages. The implementation of highly effective therapeutic schemes has led to a significant increase in the survival rate of oncology patients over the last decades. In many cases, the mortality rate in oncology patients who underwent effective treatment is caused by cardiovascular events arising as a consequence of aggressive antitumor treatment or pre-existing chronic cardiovascular diseases. Among cardiovascular complications that developed both during active treatment of the malignant neoplasm and in the longer term, literature most often mentions cardiac insufficiency. We present a clinical case of successful diagnosis and treatment of severe heart insufficiency caused by antitumor therapy with bevacizumab and osimertinib in a patient with cancer of the upper lobe of the right lung and metastases into the brain.
- Open Access
- 20 September 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (3) , 42-47
Clinical case of successful treatment of a patient with anaplastic thyroid cancer in combination with ischemic heart disease and critical multivessel coronary artery disease
The article presents a clinical case of a patient with locally advanced anaplastic thyroid cancer and concomitant cardiovascular pathology. Anaplastic thyroid cancer is a very rare and highly aggressive disease requiring long-term multistage treatment, often using cardiotoxic drugs. Combination of this pathology with ischemic heart disease affecting coronary arteries is a complex clinical problem requiring timely evaluation of cardiac risk at every stage. Treatment of this patient cohort is possible only by a multidisciplinary team of specialists.
- 20 September 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (3) , 42-47
Open AccessClinical case of successful treatment of a patient with anaplastic thyroid cancer in combination with ischemic heart disease and critical multivessel coronary artery disease
The article presents a clinical case of a patient with locally advanced anaplastic thyroid cancer and concomitant cardiovascular pathology. Anaplastic thyroid cancer is a very rare and highly aggressive disease requiring long-term multistage treatment, often using cardiotoxic drugs. Combination of this pathology with ischemic heart disease affecting coronary arteries is a complex clinical problem requiring timely evaluation of cardiac risk at every stage. Treatment of this patient cohort is possible only by a multidisciplinary team of specialists.
- Open Access
- 11 September 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
An integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.
- 11 September 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
Open AccessAn integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.
- Open Access
- 22 May 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 35-39
Clinical case of surgical treatment of a patient with multivessel coronary artery disease and abdominal aortic aneurysm in combination with malignant tumor of the larynx
Combination of oncological and cardiological pathologies is a complex clinical problem requiring a multidisciplinary team of doctors for treatment of a patient. This article presents a case of successful treatment of a patient with serious concomitant pathologies.
- 22 May 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 35-39
Open AccessClinical case of surgical treatment of a patient with multivessel coronary artery disease and abdominal aortic aneurysm in combination with malignant tumor of the larynx
Combination of oncological and cardiological pathologies is a complex clinical problem requiring a multidisciplinary team of doctors for treatment of a patient. This article presents a case of successful treatment of a patient with serious concomitant pathologies.